Featured Grant Funding

National Cancer Institute - Lymphoma SPORE ($ 12.5M)

Leukemia & Lymphoma Society - Mantle cell lymphoma SCOR ($ 2.5M) (2018-2022) (L. Kwak)

  • Project 1: Development of a unique tumor-specific, antibody therapy against mantle cell lymphoma (L. Kwak, H. Qin).
  • Project 2: Combining CAR T cells with signaling modulators for treatment of relapsed/refractory mantle cell lymphoma (S. Forman, X. Wang, E. Budde).
  • Project 3: Targeting oncogenic B cell receptor (BCR)-feedback control in refractory mantle cell lymphoma (M. Müschen, V. Ngo, R. Chen).
  • Core A: Pathology and Tissue Bank Core (J. Chan, J. Song).
  • Core B: Translational Core (S. Thomas, C. Matsumoto).

Lymphoma Research Foundation - Clinical Investigator Career Development Award (2017-2020)

Pembrolizumab plus ibrutinib for treatment of relapsed or refractory peripheral T cell lymphomas (A. Herrera).

SWOG Integrated Translational Science Center - Pilot Award (2017-2018)

Circulating tumor DNA in follicular lymphoma (A. Herrera).

International Waldenstrom’s Macroglobulinemia Foundation - Leukemia & Lymphoma Society Strategic Research Roadmap (2017-2019)

Anti-tumor and immune microenvironment responses following a first-in-human DNA Fusion Vaccine for asymptomatic lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinemia (L. Kwak, S. Thomas).

Leukemia & Lymphoma Society - Translational Research Program grant (2017-2020)

Novel antibody therapy targeting BAFF-R against drug-resistant B cell lymphomas (L. Kwak, H. Qin).

Department of Defense - Peer Reviewed Cancer Research Program (2015-2018)

Development of an antibody therapy against immunosuppressive cells in blood cancer patients (H. Qin, L. Kwak).

STOP CANCER - Research Development Award (2018-2021)

Modulating immune dynamics in cutaneous T cell lymphoma (C. Querfeld).